drugset / Trial / NCT04535271
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Timeline
- Start
- 2021-09-09
- Primary completion
- 2028-09-30
- Completion
- 2029-03-30
Publications
- Background Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014 Jul;5(3):186-92. doi: 10.4103/0976-500X.136098.
- Background www.accessdata.fda.gov/drugsatfda_docs (Trabectedin, Gemcitabine, Dacarbazine)
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dacarbazine | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Dacarbazine | Small molecule | 250 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 250 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 0.5 mg/m2 | Intravenous |